Researchers showed that IL-37 transgenic mice (IL-37tg) can markedly reduce clinical manifestations of DSS colitis, ischemia–reperfusion injury, obesity-induced inflammation, LPS-induced shock and psoriasis, and ameliorate their inflammatory cytokine productions [28]–[31]. This evidence concerns the gene IL37 and obesity due to melanocortin 4 receptor deficiency.